嵌合抗原受体 T 细胞免疫疗法的总费用。
Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy.
机构信息
Department of Pharmacy and Therapeutics, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania.
Center for Pharmaceutical Policy and Prescribing, University of Pittsburgh, Pittsburgh, Pennsylvania.
出版信息
JAMA Oncol. 2018 Jul 1;4(7):994-996. doi: 10.1001/jamaoncol.2018.0977.
Abstract
This study estimates the total costs associated with administering chimeric antigen receptor T-cell treatment.
摘要
本研究估算了与嵌合抗原受体 T 细胞治疗相关的总费用。
相似文献
1
Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy.嵌合抗原受体 T 细胞免疫疗法的总费用。
JAMA Oncol. 2018 Jul 1;4(7):994-996. doi: 10.1001/jamaoncol.2018.0977.
2
Immunotherapy: Tisagenlecleucel - the first approved CAR-T-cell therapy: implications for payers and policy makers.免疫疗法：替沙格赛定 - 首个获批的嵌合抗原受体T细胞疗法：对支付方和政策制定者的影响
Nat Rev Clin Oncol. 2018 Jan;15(1):11-12. doi: 10.1038/nrclinonc.2017.156. Epub 2017 Oct 4.
3
Safer CAR T-Cell Therapy.更安全的嵌合抗原受体T细胞疗法
JAMA. 2019 Jun 11;321(22):2155. doi: 10.1001/jama.2019.7551.
4
CAR T-cell therapy: perceived need versus actual evidence.嵌合抗原受体T细胞疗法：感知到的需求与实际证据
Lancet Oncol. 2018 Oct;19(10):1259. doi: 10.1016/S1470-2045(18)30698-3. Epub 2018 Oct 1.
5
Secondary Cancers after Chimeric Antigen Receptor T-Cell Therapy.嵌合抗原受体T细胞疗法后的继发性癌症
N Engl J Med. 2024 Feb 15;390(7):584-586. doi: 10.1056/NEJMp2400209. Epub 2024 Jan 24.
6
Acute Kidney Injury After the CAR-T Therapy Tisagenlecleucel.嵌合抗原受体T细胞疗法（CAR-T）使用替沙格利单抗后的急性肾损伤
Am J Kidney Dis. 2021 Jun;77(6):990-992. doi: 10.1053/j.ajkd.2020.08.017. Epub 2020 Oct 22.
7
Insights Into Cardiovascular Risks of Chimeric Antigen Receptor T-Cell Therapy-From Peril to Promise.嵌合抗原受体T细胞疗法的心血管风险洞察：从危险到希望
JAMA Netw Open. 2024 Oct 1;7(10):e2437157. doi: 10.1001/jamanetworkopen.2024.37157.
8
Novel targets and technologies for CAR-T cells in multiple myeloma and acute myeloid leukemia.多发性骨髓瘤和急性髓系白血病中CAR-T细胞的新型靶点与技术
Curr Res Transl Med. 2018 May;66(2):37-38. doi: 10.1016/j.retram.2018.03.006. Epub 2018 Apr 11.
9
Balancing the risks and benefits of CAR T-cell therapy.平衡嵌合抗原受体T细胞疗法的风险与益处。
Lancet Haematol. 2024 Mar;11(3):e169. doi: 10.1016/S2352-3026(24)00037-1.
10
Accounting for All Costs in the Total Cost of Chimeric Antigen Receptor T-Cell Immunotherapy.嵌合抗原受体T细胞免疫疗法总成本中的所有成本核算。
JAMA Oncol. 2018 Dec 1;4(12):1784-1785. doi: 10.1001/jamaoncol.2018.4625.
引用本文的文献
1
CAR-T cell therapy in rheumatic diseases: a review article.风湿性疾病中的嵌合抗原受体T细胞疗法：一篇综述文章。
Clin Rheumatol. 2025 Apr 26. doi: 10.1007/s10067-025-07451-7.
2
Safety, efficacy and total cost of point-of-care manufactured anti-CD19 CAR-T cell therapy in India: VELCART trial.印度即时制造的抗CD19嵌合抗原受体T细胞疗法的安全性、疗效及总成本：VELCART试验
Mol Ther Oncol. 2025 Mar 25;33(2):200977. doi: 10.1016/j.omton.2025.200977. eCollection 2025 Jun 18.
3
Therapeutic advances in multiple sclerosis: Novel therapies (immune checkpoint inhibitors, CAR-T, Anti-CD40L).多发性硬化症的治疗进展：新型疗法（免疫检查点抑制剂、嵌合抗原受体T细胞疗法、抗CD40L）
Neurotherapeutics. 2025 Jul;22(4):e00558. doi: 10.1016/j.neurot.2025.e00558. Epub 2025 Feb 27.
4
Revolutionizing Cancer Treatment: Unveiling the Power of CAR T-cell Therapy.变革癌症治疗：揭示CAR-T细胞疗法的力量。
Curr Pharm Des. 2025;31(13):1020-1036. doi: 10.2174/0113816128336391241107112957.
5
CD19 CAR-T cell therapy: a new dawn for autoimmune rheumatic diseases?CD19嵌合抗原受体T细胞疗法：自身免疫性风湿性疾病的新曙光？
Front Immunol. 2024 Dec 17;15:1502712. doi: 10.3389/fimmu.2024.1502712. eCollection 2024.
6
Should Patients Be Allowed to Pay Out of Pocket? The Ethical Dilemma of Access to Expensive Anti-cancer Treatments in Universal Healthcare Systems: A Dutch Case Study.应允许患者自掏腰包付费吗？全民医疗保健系统中获取昂贵抗癌治疗的伦理困境：一项荷兰案例研究。
J Bioeth Inq. 2024 Dec;21(4):771-784. doi: 10.1007/s11673-024-10342-2. Epub 2024 Sep 26.
7
Non-viral approaches in CAR-NK cell engineering: connecting natural killer cell biology and gene delivery.非病毒方法在 CAR-NK 细胞工程中的应用：连接自然杀伤细胞生物学和基因传递。
J Nanobiotechnology. 2024 Sep 10;22(1):552. doi: 10.1186/s12951-024-02746-4.
8
Tuning Lipid Nanoparticles for RNA Delivery to Extrahepatic Organs.调整脂质纳米颗粒以实现 RNA 向肝外器官的递送。
Adv Mater. 2024 Nov;36(44):e2401445. doi: 10.1002/adma.202401445. Epub 2024 Sep 5.
9
The Art of Bioimmunogenomics (BIGs) 5.0 in CAR-T Cell Therapy for Lymphoma Management.生物免疫基因组学（BIGs）5.0在淋巴瘤管理的嵌合抗原受体T细胞（CAR-T）疗法中的应用。
Adv Pharm Bull. 2024 Jul;14(2):314-330. doi: 10.34172/apb.2024.034. Epub 2024 Mar 10.
10
FDA-approved CAR T-cell Therapy: A Decade of Progress and Challenges.FDA 批准的嵌合抗原受体 T 细胞疗法：十年的进展与挑战。
Curr Pharm Biotechnol. 2024;25(11):1377-1393. doi: 10.2174/0113892010257212231001082741.
本文引用的文献
1
The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal.再生医学与细胞治疗产品的评估与评价：审评、经济评估与评价方法探索
Health Technol Assess. 2017 Feb;21(7):1-204. doi: 10.3310/hta21070.
2
3
Professional Fee Ratios for US Hospital Discharge Data.美国医院出院数据的专业费用比率。
Med Care. 2015 Oct;53(10):840-9. doi: 10.1097/MLR.0000000000000410.
Zotero 插件